- Molecular NameCefazolin
- SynonymCefazolin sodium; Cefazoline; Cephazolin; CEZ
- Weight454.516
- Drugbank_IDDB01327
- ACS_NO25953-19-9
- Show 2D model
- LogP (experiment)-0.58
- LogP (predicted, AB/LogP v2.0)-0.73
- pka2.54
- LogD (pH=7, predicted)-4.65
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.74
- LogSw (predicted, AB/LogsW2.0)14.91
- Sw (mg/ml) (predicted, ACD/Labs)0.05
- No.of HBond Donors2
- No.of HBond Acceptors12
- No.of Rotatable Bonds7
- TPSA234.93
- StatusFDA approved
- AdministrationIntravenous, intramuscular
- PharmacologyA first generation cephalosporin antibiotic.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding89.0
- Volume of distribution (VD)0.19 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmCefazolin is excreted unchanged in the urine.
- Half life1.8 h (given IV); 2 h (given IM)
- ExcretionRenal, unchanged
- Urinary Excretion80
- Clerance0.95 ml/min/kg
- ToxicityThe following reactions have been reported: Gastrointestinal. Diarrhea, oral candidiasis (oral thrush), vomiting, nausea, stomach cramps, anorexia, and pseudomembranous colitis. Allergic. Anaphylaxis, eosinophilia, itching, drug fever, skin rash, Stevens-Johnson syndrome. Hematologic. Neutropenia, leukopenia, thrombocytopenia, thrombocythemia. Hepatic. Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed. As with other cephalosporins, reports of hepatitis have been received. Renal. As with other cephalosporins, reports of increased BUN and creatinine levels, as well as renal failure, have been received. Local Reactions. Pain, phlebitis, induration. Other Reactions. Genital and anal pruritus (including vulvar pruritus, genital moniliasis, and vaginitis).
- LD50 (rat)N/A
- LD50 (mouse)N/A